<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To study <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> 1 (AML1) transcription factor, <z:chebi fb="0" ids="27561">ETO</z:chebi> protein, and t(8;21) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> chimeric AML1/ <z:chebi fb="0" ids="27561">ETO</z:chebi> protein in <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoiesis and in <z:hpo ids='HP_0001909'>leukemia</z:hpo>, we raised rabbit antisera to a bacterially expressed <z:chebi fb="1" ids="15841">polypeptide</z:chebi> containing amino acid residues 1 to 220 of <z:chebi fb="0" ids="27561">ETO</z:chebi> and to synthetic <z:chebi fb="7" ids="16670">peptides</z:chebi> extending from residues 528 to 548 of <z:chebi fb="0" ids="27561">ETO</z:chebi> and 32 to 50 of AML1 </plain></SENT>
<SENT sid="1" pm="."><plain>The latter was selected to have little chance of cross-reactivity with other members of the PEBP2 alpha family </plain></SENT>
<SENT sid="2" pm="."><plain>With affinity-purified reagents, we observed immunofluorescent staining for both AML1 and <z:chebi fb="0" ids="27561">ETO</z:chebi> in the nucleus of HEL, K562, and Kasumi-1 leukemic cell lines, the last from a t(8;21) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Biochemical analysis confirmed specificity of the antibodies and the nuclear localization of the antigens, the latter being exclusive for AML1 and primary for <z:chebi fb="0" ids="27561">ETO</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Immunoprecipitations of metabolically labeled <z:chebi fb="0" ids="37972">32P</z:chebi>-proteins from Kasumi-1 cells show that AML1 and <z:chebi fb="0" ids="27561">ETO</z:chebi> are phosphorylated on serine and threonine </plain></SENT>
<SENT sid="5" pm="."><plain>Investigations with <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow reveal AML1 and <z:chebi fb="0" ids="27561">ETO</z:chebi> are coexpressed in megakaryocytes and that each is expressed in a portion of the approximately 10-microns-diameter cells residing there </plain></SENT>
<SENT sid="6" pm="."><plain>Using a CD34+ enriched population mobilized to peripheral blood, we found AML1 and, unexpectedly, <z:chebi fb="0" ids="27561">ETO</z:chebi> present in these cells </plain></SENT>
<SENT sid="7" pm="."><plain>Because of this, we conclude that the expression of <z:chebi fb="0" ids="27561">ETO</z:chebi> in hematopoietic cells is not by itself leukemogenic </plain></SENT>
<SENT sid="8" pm="."><plain>Also, because <z:chebi fb="0" ids="27561">ETO</z:chebi> would not be exclusively expressed as part of chimeric AML1/<z:chebi fb="0" ids="27561">ETO</z:chebi> in leukemic patients, its presence cannot be used to monitor t(8;21) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> </plain></SENT>
</text></document>